This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuroki, T. Articles by Croce, C. M. Search for Related Content PubMed PubMed Citation Articles by Kuroki, T. Articles by Croce, C. M.

Allele Loss and Promoter Hypermethylation of VHL, RAR-ß, RASSF1A, and FHIT Tumor Suppressor Genes on Chromosome 3p in Esophageal Squamous Cell Carcinoma¹

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [T. K., F. T., S. Y., A. M., H. A., C. M. C.], and Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan [M. M.]

Promoter hypermethylation is an alternative way to inactivate tumor suppressor genes in cancer. Alterations of chromosome 3p are frequently involved in many types of cancer, including esophageal squamous cell carcinoma. Here, we investigated the methylation status and loss of heterozygosity (LOH) of 3p tumor suppressor genes. We examined the promoter methylation status of von Hippel-Lindau disease (VHL), retinoic acid receptor ß (RAR-ß), RAS association domain family 1A (RASSF1A), and fragile histidine triad (FHIT) genes in 22 esophageal squamous cell carcinoma cell lines and 47 primary tumors and corresponding noncancerous tissues by a methylation-specific PCR. In addition, we analyzed 47 paired samples for LOH at eight loci on chromosome 3p. Hypermethylation in VHL, RAR-ß, RASSF1A, and FHIT was detected in 36, 73, 73, and 50% of tumor cell lines, respectively. In primary tumors, hypermethylation in VHL, RAR-ß, RASSF1A, and FHIT was detected in 13, 55, 51, and 45%, respectively. In corresponding noncancerous tissues, hypermethylation in RAR-ß and FHIT was frequently detected in 38 and 30%, respectively, whereas no VHL hypermethylation and only 4% of RASSF1A hypermethylation were detected. Furthermore, in clinical stages I and II, hypermethylation in RAR-ß (67%) and FHIT (78%) was frequently detected, whereas no VHL hypermethylation and 11% of RASSF1A hypermethylation were detected. On the other hand, the correlation between FHIT hypermethylation and LOH at FHIT region was statistically significant (P = 0.008). Our findings suggest that hypermethylation of the RAR-ß and FHIT may play an important role in the early stage of esophageal squamous cell carcinogenesis. In addition, FHIT may be inactivated in accordance with the two-hit inactivation model, involving deletion of one allele and hypermethylation of the other.

This article has been cited by other articles:

				K. Misawa, Y. Ueda, T. Kanazawa, Y. Misawa, I. Jang, J. C. Brenner, T. Ogawa, S. Takebayashi, R. A. Grenman, J. G. Herman, et al. Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7604 - 7613. [Abstract] [Full Text] [PDF]

				K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas Ann. Onc., October 1, 2008; 19(10): 1774 - 1786. [Abstract] [Full Text] [PDF]

				L. Lei, S. Mason, D. Liu, Y. Huang, C. Marks, R. Hickey, I. S. Jovin, M. Pypaert, R. S. Johnson, and F. J. Giordano Hypoxia-Inducible Factor-Dependent Degeneration, Failure, and Malignant Transformation of the Heart in the Absence of the von Hippel-Lindau Protein Mol. Cell. Biol., June 1, 2008; 28(11): 3790 - 3803. [Abstract] [Full Text] [PDF]

				W. Yueying, W. Jianbo, L. Hailin, T. Huaijing, G. Liping, and L. Shih-Hsin ECRG1, a novel esophageal gene, cloned and identified from human esophagus and its inhibition effect on tumors Carcinogenesis, January 1, 2008; 29(1): 157 - 160. [Abstract] [Full Text] [PDF]

				L. Fu, Y.-R. Qin, D. Xie, L. Hu, D. L. Kwong, G. Srivastava, S. W. Tsao, and X.-Y. Guan Characterization of a Novel Tumor-Suppressor Gene PLC{delta}1 at 3p22 in Esophageal Squamous Cell Carcinoma Cancer Res., November 15, 2007; 67(22): 10720 - 10726. [Abstract] [Full Text] [PDF]

				D. Angeloni Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease Brief Funct Genomic Proteomic, May 24, 2007; (2007) elm007v1. [Abstract] [Full Text] [PDF]

				S. Semba, S.-Y. Han, H. R. Qin, K. A. McCorkell, D. Iliopoulos, Y. Pekarsky, T. Druck, F. Trapasso, C. M. Croce, and K. Huebner Biological Functions of Mammalian Nit1, the Counterpart of the Invertebrate NitFhit Rosetta Stone Protein, a Possible Tumor Suppressor J. Biol. Chem., September 22, 2006; 281(38): 28244 - 28253. [Abstract] [Full Text] [PDF]

				S. Semba and K. Huebner Protein Expression Profiling Identifies Cyclophilin A as a Molecular Target in Fhit-Mediated Tumor Suppression Mol. Cancer Res., August 1, 2006; 4(8): 529 - 538. [Abstract] [Full Text] [PDF]

				Y. Li, X. Zhang, G. Huang, X. Miao, L. Guo, D. Lin, and S.-H. Lu Identification of a novel polymorphism Arg290Gln of esophageal cancer related gene 1 (ECRG1) and its related risk to esophageal squamous cell carcinoma Carcinogenesis, April 1, 2006; 27(4): 798 - 802. [Abstract] [Full Text] [PDF]

				X.-f. Wang, D. Z. Qian, M. Ren, Y. Kato, Y. Wei, L. Zhang, Z. Fansler, D. Clark, O. Nakanishi, and R. Pili Epigenetic Modulation of Retinoic Acid Receptor {beta}2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3535 - 3542. [Abstract] [Full Text] [PDF]

				X.-c. Xu, J. J. Lee, T.-T. Wu, A. Hoque, J. A. Ajani, and S. M. Lippman Increased Retinoic Acid Receptor-{beta}4 Correlates In vivo with Reduced Retinoic Acid Receptor-{beta}2 in Esophageal Squamous Cell Carcinoma Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 826 - 829. [Abstract] [Full Text] [PDF]

				M. Takaoka, H. Harada, C. D. Andl, K. Oyama, Y. Naomoto, K. L. Dempsey, A. J. Klein-Szanto, W. S. El-Deiry, A. Grimberg, and H. Nakagawa Epidermal Growth Factor Receptor Regulates Aberrant Expression of Insulin-Like Growth Factor-Binding Protein 3 Cancer Res., November 1, 2004; 64(21): 7711 - 7723. [Abstract] [Full Text] [PDF]